T. Rowe Price Associates
THRX

T. Rowe Price Associates’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

T. Rowe Price Associates’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,216,500
Closed -$3.27M – 2937
2023
Q3 		$3.27M Sell
1,216,500
-39,509
-3% -$155K ﹤0.01% 1300
2023
Q2 		$11.7M Sell
1,256,009
-69,556
-5% -$685K ﹤0.01% 1051
2023
Q1 		$11.8M Buy
1,325,565
+11,657
+0.9% +$114K ﹤0.01% 1028
2022
Q4 		$6.54M Sell
1,313,908
-67,581
-5% -$396K ﹤0.01% 1129
2022
Q3 		$8.01M Sell
1,381,489
-3,794
-0.3% -$26.8K ﹤0.01% 1103
2022
Q2 		$7.66M Sell
1,385,283
-51,333
-4% -$424K ﹤0.01% 1360
2022
Q1 		$16.3M Buy
1,436,616
+137,129
+11% +$1.47M ﹤0.01% 1285
2021
Q4 		$16.2M Buy
+1,299,487
New +$19.6M ﹤0.01% 1331

Other funds holding THRX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

T. Rowe Price Associates's THRX Position: Q4 2023 in Review

T. Rowe Price Associates sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q4 2023, closing a stake of 1,216,500 shares — an estimated $3.27M sold.

T. Rowe Price Associates first reported a position in THRX in Q4 2021 and held it in 8 quarters. The position peaked at $16.3M in Q1 2022. 70 funds tracked by Wall St. Rank hold THRX as of Q4 2023.

  • T. Rowe Price Associates reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,216,500 Theseus Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $3.27M.
  • T. Rowe Price Associates first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
  • T. Rowe Price Associates's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $16.3M in Q1 2022.
  • 70 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.